



Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Company Adds Former Executive at Takeda, Pfizer, AstraZeneca, GSK and Merck to Leadership Team

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- [Reunion Neuroscience Inc.](#) (NASDAQ: REUN, TSX: REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D. as the Company's Chief Medical Officer, effective immediately. Dr. Alexander will report to Greg Mayes, Reunion's President and CEO.

"Robert's extensive experience as a biotech industry veteran will be crucial as we continue to progress RE104 through the clinic and approach our Phase 2 study launch in postpartum depression," said Mr. Mayes. "Following Reunion's successful interim data analysis for its Phase 1 trial with lead asset RE104, Robert will further guide us in advancing RE104 to the next stage of development for the millions of patients in need."

Dr. Alexander previously served as Vice President and Head, Clinical Science, in the Neuroscience Therapeutic Area Unit at Takeda Pharmaceuticals, managing all clinical trials in neuroscience from Phase 1 through 3. Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company. Dr. Alexander also held various other senior leadership roles at AstraZeneca, GlaxoSmithKline (GSK) and Merck & Co and received his M.D. degree from The University of Chicago Pritzker School of Medicine. He is certified by the American Board of Psychiatry and Neurology and specializes in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.

"What separates Reunion from the other CNS-focused biotech companies working with psychedelic medicine today is two-fold: first, its truly innovative asset, RE104, is the only 4-OH-DiPT drug in development. Second, the Company's strong intellectual property position gives Reunion a significant competitive advantage over others in the space," added Dr. Alexander. "As the Company looks to progress RE104 through the clinic in an industry that is ripe for innovation – not to mention with patients all over the world who are in dire need of a new solution – I am confident in Reunion's role as an industry leader looking to disrupt the mental health treatment landscape as we know it."

About Reunion Neuroscience Inc.

Reunion is committed to developing innovative therapeutic solutions for underserved mental health conditions. The Company's lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions. The U.S. Patent and Trademark Office has granted the Company a patent for the claims related to RE104, granting it exclusive rights to the composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including RE104. The patent will provide protection until 2041. Reunion is also developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.

Learn more at <https://www.reunionneuro.com>.

Follow us on [LinkedIn](#), [Twitter](#) and [Instagram](#).

To be added to the Reunion Neuroscience email list, please opt-in at <https://investors.reunionneuro.com/resources/email-alerts>.

Cautionary Note Regarding Forward-Looking Information

This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC's website at www.sec.gov.

Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Reunion Neuroscience:

Greg Mayes
President & CEO
(215) 696-9659

gmayer@reunionneuro.com

Media Contact:

Shana Marino
KCSA Strategic Communications
(347) 487-6189
reunion@kcsa.com



Source: Reunion Neuroscience Inc.